Indications of satelizumab (Anshiping)

Satralizumab (Satralizumab) is an injection approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD; an autoimmune disease of the nervous system that affects the nerves in the eyes and spinal cord). Satelizumab is a drug called an interleukin-6 (IL-6) receptor inhibitor, which works by blocking part of the immune system's activity in certain areas of the nervous system that can damage people with neuromyelitis optica spectrum disorder. Satclizumab comes as a solution (liquid) that is injected subcutaneously (under the skin), and the doctor may decide that the patient or caregiver can give it at home.